Are We Closer to Personalized Medicine in MS?

Slides:



Advertisements
Similar presentations
April 2005 How Patients Can Benefit From Molecular Imaging Paula M. Jacobs, Ph.D Vice President Advanced Magnetics, Inc.
Advertisements

Upfront Combination Therapy vs Step-Up Approach for PAH:
Monitoring and Modifying Treatment in PAH
Making Decisions With Your Osteoarthritis Patients
NOACs In Long-term VTE Treatment: A State Of The Art Review
Objective Assessment of RA: Expanding the Horizons
The ABCs of AF.
Beyond Supportive Care for Lower-Risk Myelodysplastic Syndrome
PrEP Effectiveness. Preexposure Prophylaxis Translating the Clinical Trials Into Clinical Practice.
Modifying Disease Course in Alzheimer's Disease
Current Controversies in Multiple Sclerosis Management
Charting Progress in MS Diagnosis and Treatment for Today and Tomorrow
Cardiac Biomarkers.
Emerging Data and Clinical Advances in MS:
Stepping Up Asthma Control for Effective Management
Oral Anticoagulants in AFa,b A Brief History.
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Challenges in Managing Progressive Multiple Sclerosis
A Unified Approach to Anticoagulant Therapy in ACS: What's Missing?
Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS
Seizures in the Elderly: Treatment and Special Considerations
The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer.
Selected Causes of Cardiac Injury PEACE Trial High-Sensitivity Biomarker Substudy.
Is RA Treatment Addressing the Real Needs of Patients?
Managing IBD.
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
EHL Technologies in Hemophilia Care
Program Goals Disclaimer Overview Assessing Disease Activity.
Real-World Evidence in VTE
Program Goals Overview Glatiramer Acetate 3 Times a Week.
Charting Progress in MS Treatment:
Comments on design and sequence of biomarker studies
Personalized Therapy in Relapsed or Refractory CLL
Advancing the Treatment of IBD With Biologics
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
Treating to Target in MS
EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.
What's New on Interventions for Lower Limb Spasticity?
Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.
Identifying High-Risk AF Patients
Program Goals Overview Is NEDA a Reasonable Target?
When Is Intrathecal Drug Delivery Appropriate?
Treatment-Resistant Schizophrenia
Cancer-Associated Thrombosis
Managing Your Patient’s Maintenance Therapy for Multiple Myeloma
Program Goals Disclaimers Defining Refractory Seizures.
New ELN Recommendations
Add-On Therapy to Insulin in T1DM Management
Incorporating Prostacyclins Into Practice
Program Goals Background: Anticoagulation in Patients With VTE.
Program Goals Overview Natalizumab Natalizumab: Recent Label Changes.
Clinical Challenges and Updates in Managing Seizure Clusters
The Role of Measurable Residual Disease in AML
Program Goal. Program Goal Disclaimer Overview.
The ABCs of AF.
Disease Burden of VTE Phases of VTE Treatment.
Individualizing Therapy for RA: Are We There Yet?
5 Good Minutes on Atrial Fibrillation-related Stroke
Program Goals Overview Is NEDA a Reasonable Target?
What is “AF Burden”?. What is “AF Burden”? AF Burden and Stroke Risk ASSERT Study.
When Is Intrathecal Drug Delivery Appropriate?
Issues in Patients With Severe Epilepsy
Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.
Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice.
What's New in PAH?.
Rethinking Risk Stratification for Nonischemic HF:
Understanding the Role of Disability in MS Management
The Power of As-Treated Analyses
Patient Heterogeneity in CD
Presentation transcript:

Are We Closer to Personalized Medicine in MS?

Disclaimers

Program Goals

What Is Personalized Medicine?

What Is Personalized Medicine? (cont)

Prognostic Indicators

Biomarkers: JC Virus Antibody Index

Biomarkers

Patient Factors

Drug Factors

Assessing Risk

Experience With MS Drugs: Clinical Practice vs Clinical Trials

Monitoring Response

Monitoring Response: Modified Rio Score

Monitoring Response (cont)

Switching and Sequencing Therapy

Risk Stratification at Diagnosis -- and Beyond

On the Horizon: Agents in Development

On the Horizon: Reduced Injections

Summary and Key Points

Abbreviations

References

References (cont)

References (cont)

References (cont)

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.